Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

UK health authorities are investigating pancreatitis cases linked to weight-loss drugs like Ozempic and Mounjaro. We spoke to doctors for clarity on risks, side effects, and the role of genetics.

Two of the distinguished in the latest edition of the Fronteras del Conocimiento FBBVA, endocrinologist Daniel J. Drucker and ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.